Wall Street analysts forecast that Catalent, Inc. (NYSE:CTLT – Get Rating) will post earnings of $1.13 per share for the current quarter, Zacks reports. Six analysts have provided estimates for Catalent’s earnings. The highest EPS estimate is $1.18 and the lowest is $1.05. Catalent reported earnings of $1.16 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 2.6%. The company is scheduled to issue its next earnings results on Monday, January 1st.
On average, analysts expect that Catalent will report full-year earnings of $3.79 per share for the current fiscal year, with EPS estimates ranging from $3.70 to $3.84. For the next financial year, analysts forecast that the business will report earnings of $4.24 per share, with EPS estimates ranging from $4.09 to $4.39. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Catalent.
Catalent (NYSE:CTLT – Get Rating) last posted its quarterly earnings results on Tuesday, May 3rd. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.10. Catalent had a net margin of 10.72% and a return on equity of 15.07%. The firm had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.22 billion. During the same period in the previous year, the firm posted $0.78 earnings per share. The business’s revenue was up 20.9% compared to the same quarter last year.
CTLT traded up $0.69 during midday trading on Thursday, hitting $98.51. The company had a trading volume of 5,047 shares, compared to its average volume of 1,624,738. Catalent has a 52 week low of $86.34 and a 52 week high of $142.64. The company has a quick ratio of 2.25, a current ratio of 2.89 and a debt-to-equity ratio of 0.90. The company has a market capitalization of $17.65 billion, a price-to-earnings ratio of 35.69, a PEG ratio of 1.60 and a beta of 1.44. The stock’s 50 day moving average price is $100.94 and its 200 day moving average price is $110.19.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Catalent by 2.7% in the first quarter. Vanguard Group Inc. now owns 18,971,342 shares of the company’s stock valued at $2,103,921,000 after purchasing an additional 492,071 shares during the period. BlackRock Inc. increased its holdings in Catalent by 4.2% during the 1st quarter. BlackRock Inc. now owns 15,631,020 shares of the company’s stock worth $1,733,479,000 after acquiring an additional 632,934 shares during the period. Capital World Investors increased its holdings in Catalent by 10.6% during the 3rd quarter. Capital World Investors now owns 10,632,004 shares of the company’s stock worth $1,414,801,000 after acquiring an additional 1,018,902 shares during the period. State Street Corp increased its holdings in Catalent by 3.8% during the 1st quarter. State Street Corp now owns 7,126,429 shares of the company’s stock worth $790,321,000 after acquiring an additional 261,686 shares during the period. Finally, Veritas Asset Management LLP increased its holdings in Catalent by 15.3% during the 1st quarter. Veritas Asset Management LLP now owns 6,999,686 shares of the company’s stock worth $776,265,000 after acquiring an additional 929,400 shares during the period. Hedge funds and other institutional investors own 98.05% of the company’s stock.
About Catalent (Get Rating)
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
- Get a free copy of the StockNews.com research report on Catalent (CTLT)
- A Reversal In The S&P 500 Is Confirmed
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.